Bioprinting

Additive Manufacturing in Dentistry (Premium)

Dentistry seems to be the potential breakthrough industry to manifest many 3D printing enthusiasts’ dreams of mass customization, point-of-care delivery, and local manufacturing hub for dental professionals, reducing inefficiency and costs. Over the past several years, 3DHEALS has invited many different stakeholders to share their experiences, ranging from material innovation, and software development, to new clinical workflows. Applications ranging from surgical guides, implants, dentures, and night guards are among the new applications gaining increasing attention either in the startup world or the industry at large, in addition to the existing billion-dollar market of dental aligners. The collective thought is that 3D printing can do more and more in parallel to the maturation of technologies. In this 90-minute webinar, we invite experts with unique perspectives about the current status and near future of dental 3D printing, including international clinicians, startup founders, and industry veterans. 

Speakers:

Dr. Ioanna Gidarakou

Dr Ioanna Gidarakou received her dental degree from the Aristotle University of Thessaloniki, Magna Cum Laude. She then completed her orthodontic specialty at Eastman Dental Center, University of Rochester, NY. At the same time, she received her TMJD degree and completed a 1-year fellowship on genetics at the Pediatric Department, School of Medicine, University of Rochester, NY. She pursued her PhD thesis on Class II growing patients at the Aristotle University of Thessaloniki. Dr Gidarakou has been actively involved in academics, teaching pre- and post-graduate students, giving lectures worldwide and publishing numerous articles in prestigious orthodontic journals. She currently maintains 2 orthodontic practices in Katerini and Litochoro, in Central Macedonia, Greece. She is married with 3 children.

Gustavo Mendonca

Dr. Gustavo Mendonça is a Professor at the Department of General Practice at the Virginia Commonwealth University. He received his DDS from the Federal University of Uberlandia, Brazil. He also completed his postgraduate training in Prosthodontics and master’s degree in Oral Rehabilitation from the same school. In 2008 he finished his PhD in Genomic Sciences and Biotechnology at the Catholic University of Brasília, Brazil. Dr. Gustavo Mendonça is also a Fellow and a Diplomate of the Academy of Osseointegration. Dr. Gustavo Mendonça’s research interests focus has been related to the use of CAD/CAM materials and 3d printing for clinical use in dentistry and research applications. He also has worked in vitro and in vivo on the effect of osseointegration of implants and biomaterials. In addition to his research, Dr. Mendonça is dedicated to teaching and mentoring the next generation of dental professionals. Dr. Mendonça is passionate about providing high-quality, patient-centered care and ensuring that his students are well-prepared to meet the challenges of the dental profession.

Iain Mcleod

Iain is originally from Scotland and studied B.Eng. Computer Engineering and Electronics at Napier University Edinburgh. On graduating in 1994, he became a founder of a software company specialising in hardware simulation. He then moved to Denmark in 2004, joining 3Shape back in 2007 to develop 3D scanning and CAD software for the digital workflow in audiology. After completing an MBA at Copenhagen Business School in 2019, he got even closer to the world of 3D printing and material development with joining the 3D printer company Formlabs. Iain is now the CEO of H3D, a SaaS company that has developed a fully automated high volume AI solution that removes the need to use CAD software in the digital dentistry workflow.

Dr. Khaled Kasem

Khaled Kasem

Dr. Khaled Kasem has more than 25 years of experience in his field. He currently works exclusively in orthodontics being the chief of orthodontists at Impress while also combining his work at the University of Barcelona as research coordinator in the orthodontic
department. He has studied a master’s degree in Orthodontics and has a diploma in advanced techniques in dentistry. He has publications in renowned journals such as the American Journal of Orthodontics & Dentofacial Orthopedics or Photomedicine & Laser Surgery.

Impress is the #1 European digital orthodontic brand. The company was established in Barcelona in 2019, and since then it has revolutionized the invisible orthodontic sector with the best team of professionals specialized in making people smile and the latest technology applied to the diagnosis, treatment, and follow-up of all cases. In 4 years, Impress has managed to position itself as the European leader in the orthodontic sector with its award-winning invisible orthodontic treatment.

After raising $125 million earlier in 2022, the funding was earmarked to further expand its presence across Europe, as well as propel the orthodontic experience further into the digital realm. Impress is currently present in more than 160 cities in 8 different countries: Spain, Portugal, Italy, United Kingdom, France, Ukraine, Germany and the United States.

Gino Balistreri

Global Market Development Lead – HP Personalization & 3D Printing

Gino Balistreri is engaging with organizations in the dental and medical industry to increase the rate of additive manufacturing adoption, particularly focusing on orthodontic production applications using HP’s Multi Jet Fusion 3D printing technology. Driven by his dedication to healthcare and his mission to enhance quality of life through new technology, Gino has successfully steered cross-functional teams to grow strategic customers to high-volume additive production in fleets with HP’s 3D printers.

Prior to leading a team in developing production applications, Gino served as a Global Product Manager, where he effectively led teams in launching products that automated key steps in scaling MJF production at HP’s largest customers across various industries.

Gino pursued his studies at universities in the Netherlands, Hong Kong, and Mexico, obtaining an MSc and BSc in Industrial Engineering and Management from the University of Twente.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Bioprinting Cancer (Premium)

Cancer, what a modern-day existential threat to humanity, is a word that triggers a cringe from the most fearless. Over the past decades in modern medicine, we have made much progress in cancer care, ranging from diagnosis, surgical advancements, to therapeutics. Despite that, cancer is surpassing heart diseases as a leading cause of death in the United States in 2020. [Ref] The demand for faster diagnostics and better treatment is driving researchers to technologies like 3D printing and 3D bioprinting. 

Speakers:

Dr. Antti Arjonen

Cancer research, microscopy, cell biology, image-based high-throughput screening, 3D bioprinting

Dr. Karolina Valente

Karolina has a B.Sc. and M.Sc. in Chemical Engineering, and a Ph.D. in Mechanical Engineering. She has deep expertise in tissue engineering, 3D bioprinting, and oncology. Karolina has published multiple peer-reviewed papers and is currently an Assistant Teaching Professor at the University of Victoria and the CEO & CSO of VoxCell BioInnovation.

Raphael Lichtnecker

I got my Master´s degree in Pharmaceutical Bioprocess Engineering at Technical University Munich. Afterwards I started as Business Development Manager at ViscoTec where I am responsible for the technology transfer of the progressive cavity pump to the bioprinting sector. I´m in this position for four years now.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Bioprinting for Drug Discovery and Development (Premium)

3D bioprinting is a relatively new technology that has the potential to revolutionize drug discovery and development. Here are some ways 3D bioprinting can help in this field: 1) Generating realistic in vitro models: 3D bioprinting can create three-dimensional tissue structures that closely mimic the in vivo environment. These structures can be used to test the efficacy and toxicity of drugs in a more realistic setting than traditional two-dimensional cell culture methods. This can help researchers identify promising drug candidates earlier in the drug development process, which can save time and resources. 2) Personalized medicine: 3D bioprinting can be used to create patient-specific tissues or organs for drug testing. This can help identify drugs that are effective for a particular patient population, as well as identify potential adverse effects that may not be detected in traditional preclinical testing. 3) High-throughput screening: 3D bioprinting can enable the creation of large numbers of complex tissue models in a relatively short amount of time. This can allow for high-throughput screening of potential drug candidates, which can speed up the drug discovery process and reduce costs. 4) Target identification: 3D bioprinting can help researchers identify new drug targets by enabling the creation of more complex tissue structures that better mimic the in vivo environment. This can provide researchers with a more complete understanding of disease biology and help identify new therapeutic targets. 5) Overall, 3D bioprinting has the potential to improve the drug discovery and development process by enabling the creation of more realistic in vitro models, accelerating the drug discovery process, and improving patient outcomes through personalized medicine. In this highly anticipated event, we invite critical stakeholders in the 3D bioprinting drug development ecosystem to update the community on where we are in terms of technologies and commercialization of the technologies.

Speakers:

Andrew Lee

Andrew Lee is a co-founder at FluidForm, a 3D biofabrication company looking to change the way we think about tissue engineering and regenerative medicine. He currently is the Product Manager for the Cardiac Group at FluidForm. He received his Ph.D. in Biomedical Engineering at Carnegie Mellon University where his focus on muscle tissue engineering leveraged biofabrication to create skeletal and cardiac tissue models with complex tissues architecture as well as physiologically relevant contractile functions. This work resulted in a publication in the journal Science and is now utilized as the platform technology for FluidForm as it builds out a portfolio of tissues for research, repair, and replacement.

Kevin Vos

Kevin is the Director of Preclinical R&D at VoxCell BioInnovation. He acquired his Bachelor’s of Science from the University of Victoria in Biochemistry. He then completed his Ph. D. also from the University of Victoria in physical chemistry studying the photo-physical characterization of supramolecular complexes. After his Ph.D., Kevin completed a post-doctoral fellowship at the University of Calgary working with the World Health Organization studying the decontamination and reuse of PPE during the SARS-CoV-2 pandemic. Kevin then joined VoxCell in December 2021, as a tissue engineering scientist where he now leads the development of VoxCell’s tissue models.

Orquidea (Orchid) Garcia, PhD, MS

As a Johnson & Johnson Fellow and Lead for 3D Bioprinting and Tissue Regen Technologies, Orquidea (Orchid) Garcia is the technical lead for 3D bioprinting, and related tissue regen technology development. She is responsible for evaluation and execution of technical strategies and new technology integration to develop a new class of next-generation healthcare solutions. Orchid works closely with internal business partners, as well as technology, academia and government partners to develop J&J’s bioprinting capabilities.    

Orchid has extensive experience identifying novel technologies through scientific discovery and translating them into patentable, marketable technologies both in industry and academia. Having served as the scientific subject matter expert on numerous initiatives, she brings a keen understanding of world-wide technical, scientific, regulatory and policy issues that face the business. Orchid has also held various positions within J&J and in industry in Clinical Affairs, Medical Affairs and Regulatory Affairs. 

Isabella Bondesson

isabella bondesson

Isabella Bondesson is a Field Application Scientist at CELLINK, the global leading bioprinting company. Isabella has a BioTech Engineering degree from Chalmers Institute of Technology, and she joined CELLINK in 2018 as part of the R&D team to develop novel methods in tissue model printing. During her time at CELLINK Isabella has acquired expertise in multiple areas of bioprinting and is today leading the EMEA Application team who work with consulting, educating, and supporting customer needs within various aspect of 3D Bioprinting. As the leading 3D bioprinting company, CELLINK is committed to providing the most advanced 3D bioprinting products, services and technologies needed to understand and master biology. CELLINK develops technologies that democratize 3D bioprinting – providing the leading researchers in the world the tools they need to create the future of health.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

In Silico Simulation for Medtech and Biopharma (Premium)

In-silico simulation refers to using computer modeling and simulations to predict the behavior of biological systems or processes. It is an increasingly important concept for future medical device and drug development. The benefits of in-silico simulation include lowering costs, reducing animal testing, improving accuracy and safety, and clarifying regulatory pathways. This virtual event aims to illuminate the revolutionary potential of in silico simulation in not only 3D printed devices but also medical technology in general and biopharmaceuticals, led by field experts and thought leaders. From drug discovery to medical device design, participants will gain exclusive insights into how computational modeling and simulation reshape the landscape of healthcare innovation. Witness how virtual prototyping and predictive modeling accelerate novel therapies’ development and optimize treatment strategies. This is an event you must not miss.

Speakers:

Simon Sonntag

Dr. Simon Sonntag, CEO & Co-Founder of Virtonomy, has been working in the medical device field for over a decade and has experienced first-hand the challenges of developing and bringing a medical device to market and in clinical practice. Using simulation technology in this field for over ten years now, he has seen the tremendous potential of combining it with digital patient twins – not only to support medical device development but also for the regulatory process and clinical trials. He learned that there is a huge demand from the industry to reduce the time, cost, and risk involved in developing medical products, and these so-called in silico methods can achieve this. Therefore, in 2020 he co-founded Virtonomy with the clear mission to change this industry. Virtonomy stands as a pioneer in the realm of digital patient twins, introducing an end-to-end platform that seamlessly merges real world patient data, artificial intelligence, multiphysics simulations, and predictive analytics to support the medical industry. Virtonomy addresses a significant problem: mitigating the elevated risks, complexities, and time constraints entailed in medical device development, ultimately streamlining the journey to market introduction. Utilizing their advanced technology, they enable medical device developers to conduct product development and testing in the computer, reducing traditional in vivo (animal/human) and in vitro (laboratory) tests with so-called in silico experiments (computer). This makes it possible to explore the interaction of the medical device with physically accurate modeling of the in vitro setup or anatomy of the target population based on real patient data as input. Backed by the FDA and EU Commission, it’s set to cover over 40% of approvals via virtual patients and simulations. The vision of Virtonomy extends to personalized medicine in the future.

Kelsey Crossman

American administrative professional with experience in Business Development in Medical Simulation and Marketing of a European Contract Research Organization managing pharmaceutical trials and medical device studies. Twelve years of experience in complex medical/administrative document management in both private and corporate medical offices and metropolitan area hospitals. Currently, she is the business development manager for Simq GmbH.

Anthony Fejes

Dr. Anthony Fejes holds undergraduate degrees in biochemistry and Independent Studies (Bioinformatics) from the University of Waterloo, as well as a Masters degree in Microbiology & Immunology and a PhD in Bioinformatics from the University of British Columbia. Anthony started his science career as the scientific co-founder and Chief Scientific Officer at Zymeworks Inc, before working for companies such as Fabric Genomics and Tenaya Therapeutics in the Bay Area and New York based SolveBio. His experience pairs over 20 years of professional experience as a programmer with a deep background in genomics, biochemistry and data analysis, as well as a decade of management and startup experience. He is CEO and co-founder at HTuO Biosciences.

Steven Kreuzer

Dr. Steven Kreuzer is a Senior Managing Engineer at Exponent Inc, a scientific and engineering consulting company, based in the Natick, MA (Boston) office. Dr. Kreuzer received his Ph.D. in Mechanical Engineering from the University of Texas at Austin and has been a consultant with Exponent since 2013. He specializes in stress analysis using both experimental and computational approaches, which include finite element analyses and custom mechanical systems. He has worked with numerous companies and projects, supporting everything from design assessments to analyses and tests supporting regulatory submissions. He has been an active participant in the Living Heart Project with Dassault Systèmes since its inception. He serves as a co-lead of the modeling team on the FDA / Dassault ‘ENRICHMENT’ in silico clinical trial. Dr. Kreuzer has applied his expertise to numerous domains, including electronics, aerospace, energy storage, and biomedical applications.

Peter Eltes

Peter Eltes

Dr. Péter Endre Éltes is a board-certified spine surgeon who has authored over 30 scientific publications and supervised multiple medical and engineering students throughout his academic career.
He has been devoted to biomechanical research and clinical practice at the National Center for Spinal Disorders in Budapest, Hungary.
In 2018, Dr. Éltes co-founded and has since led the In Silico Biomechanics Laboratory. Here, he delved into the intricate world of patient-specific spinal care with the vision of establishing novel techniques to enhance the quality of everyday clinical practice. To achieve this, he introduced various cutting-edge technologies such as surgery planning and finite element modeling, all tailored to the individual patient. Additionally, he developed and implemented a workflow to utilize 3D printing for improved patient outcomes.

Moderators: 

Zsolt Pásztor

Zsolt Pásztor

Zsolt is a passionate 3D printing specialist in titanium 3D Printing and surface treatment.
Zsolt is co-founder and Managing Director of PREMET, a 3D-printing-focused innovative medical device producer. PREMET specialises in the manufacturing of dental products and custom-made human and veterinary implants. It puts a high emphasis on R&D, covering all steps of production, and has been involved in several international projects. PREMET pays special attention to tests and simulations, including in-silico simulations. PREMET has ISO 9001 and ISO 13485 certifications.
In addition to his professional activities, Zsolt plays a leading role in different organizations. He is a Community Manager at 3DHEALS, co-founder and Vice President of the Hungarian Additive Technology Association, and Leader of the “3D Printing in the Health Sector” working group of MediKlaszter, an accredited Med Tech cluster. In MediKlaszter, he also acts as Director of International Relations.
Zsolt also has sound experience in preparing and implementing international R&D and capacity-building projects.

Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Printing in Hospitals (Premium)

In recent years, many hospitals have started making a shift, from using medical images primarily for diagnostic purposes, to integrating them in patient-specific surgical planning. This has created enormous advantages for hospitals and their patients and is largely supported by the clarifying regulatory landscape, increased governmental support, new public and private initiatives, and the expanding role of the radiologist as an imaging expert. As part of this, an increasing number of hospitals across the world have integrated the practice of 3D printing into their medical care. Hospitals are recognizing the added value it brings to personalized patient care and the countless possibilities that are becoming a reality, in creating better treatment options.

Speakers:

Robert Hannan, MD

Director, CV Surgery Advanced Projects Laboratory | Medical Director, Quality, Nicklaus Children’s Health System | Cardiovascular Surgeon, Nicklaus Children’s Hospital

Robert Hannan, MD

Dr. Hannan holds multiple patents of medical devices, and developed Real Time Outcomes described above. His interests include delivery, measurement and transparency of quality medical care, advanced imaging, immersive technologies for patient care, and the use of innovation in clinical care and education.

Shafkat Anwar

Associate Professor of Pediatrics and Radiology, University of California San Francisco

Shafkat Anwar

Dr. Shafkat Anwar is a pediatric cardiologist at the University of California San Francisco. He specializes in non-invasive cardiac imaging, including echocardiography and cardiac magnetic resonance imaging (MRI). At UCSF, he is the Director of the Pediatric Heart Center’s Cardiac MRI and 3D+ Programs. He has founded two hospital-based 3D printing Centers – the first at Washington University in St. Louis, and currently he co-Directs UCSF’s Center for Advanced 3D+ Technologies (CA3D+). He is involved in several national and international collaborations related to 3D modeling and 3D printing. He is a founding member and the inaugural Chair of the Society for Cardiovascular Magnetic Resonance’s Advanced 3D+ Visualization Special Interest Group. Dr. Anwar completed his Residency in Pediatrics at Children’s National Medical Center, followed by a research fellowship at the National Institutes of Health. He completed his Pediatric Cardiology Fellowship at Cleveland Clinic, followed by Fellowship in Cardiac Imaging at Children’s Hospital of Philadelphia.

Muhanad Shraiteh

Muhanad recently graduated with a master’s in bioengineering and a bachelor’s in mechanical engineering. He joined the Cardiovascular Surgery Advanced Projects Lab last year and is working on innovative design and development ideas that have an impact on people’s lives and improve standards of care.. Muhanad’s research interests and past projects include topics such as biomechanics and global health engineering.

Imre J. Barabás

Imre J. Barabás

Imre is the leader of the Semmelweis 3D Centre (SE3D) at the most prestigious Semmelweis University in Budapest, Hungary. Imre works as a cardiac surgeon at Semmelweis University while running the center. His Ph.D. topic was a patient-specific 3D printed exoskeleton for left ventricle assist device implantation. Imre has gained experience during the development and licensing of the exoskeleton under the medical device regulation. Imre is the CEO and Founder of the 3D Guide Ltd. using the exoskeleton patent. The SE3D is a facility for 3D printing technology at Semmelweis University based on the three pillars of the university: patient care, education, and research. My mission is to promote 3D printing technology and build community among those clinicians using 3D technology at the university. The capability of 3D technology is a personalized and safer decision-making tool in clinicians’ hands. Imre has introduced a new undergraduate course called Basics of Digital Medicine in 2021. My goal is to give practical knowledge to medical students about 3D technology. The curriculum covers the full spectrum of medical 3D technology, including data capture, DICOM data transformation, segmentation, 3D printing, and post-processing printed objects. 3D printing is still relatively new learning and teaching tool for medical education. Patient-specific models with anatomical fidelity made from imaging datasets can significantly improve a new generation of surgeons’ knowledge and skills. The SE3D Centre offers a cooperation platform between researchers and clinicians under my leadership. My vision is to find new ways to address old and new medical issues through frontier experiments.

Kerim Genc

Kerim Genc

Kerim Genc is the Business Development Manager for the Simpleware Product Group at Synopsys. He joined Simpleware in 2011 and is currently responsible for managing global sales, business development, partnerships and technical marketing content development, with a significant focus on image-based patient specific workflows for 3D Printing and surgical guides/planning. He received his BS and MS in biomechanics from the University of Calgary and the Pennsylvania State University respectively, and completed his PhD in Biomedical Engineering at Case Western Reserve University, examining countermeasures to and computational models of spaceflight induced bone loss and fracture risk.

Thomas Haglund

Thomas Haglund

Thomas’ graduate studies were in cardiac tissue engineering before joining the team at Nicklaus Children’s. Thomas has been instrumental in operationalizing 3D printing and Mixed Reality at the Nicklaus Children’s Hospital since 2018. With the help of generous donors, the CVS APL has touched the lives of hundreds of children and their family.

Dr. Stephen Ryan

Dr. Stephen Ryan is a practicing physician and co-founder of PolyUnity Tech. He has explored Additive Manufacturing applications in healthcare for over 6 years as a researcher and entrepreneur. He has been involved in the creation of many 3D Printed products including medical simulations, patient specific medical devices, PPE and end use hospital equipment. His current role is to build relationships with hospital stakeholders to better understand regulatory considerations and advocate for the adoption of additive manufacturing services within the healthcare ecosystem.

3D Printing and Bioprinting Bones (Premium)

3D printing and bioprinting to regenerate bone both are promising for the regeneration of bone tissue. It uses 3D printing to create acellular scaffolds or 3D bioprinting bio-inks that contain living cells and growth factors to promote bone growth. This technology has the potential to create exact replicas of damaged bone, which could then be implanted in the body to help regenerate lost tissue. The process begins with scanning the bone defect to create a 3D model of the desired bone structure. Then, biomaterials or bio-ink containing stem cells and growth factors are printed in the desired structure based on the 3D models. The scaffold acts as a supportive structure for the cells, which are then allowed to grow in the desired shape. Once the cells have grown and matured, they can then be implanted into the patient’s body. This technology has been successfully used to regenerate bone in animals and is now being tested in human clinical trials. Some of the forerunners in the field include Osteopore (Singapore), Ossiform(Denmark, previously known as Particle 3D), DimensionInx(U.S., Chicago), and Cerhum(Belgium). In this upcoming virtual event, we invite all stakeholders with different backgrounds to learn and participate focusing on how we can use 3D printing to regenerate bone tissues.

Speakers:

Raphael Lichtnecker

Raphael Lichtnecker

I got my Master´s degree in Pharmaceutical Bioprocess Engineering at Technical University Munich. Afterwards I started as Business Development Manager at ViscoTec where I am responsible for the technology transfer of the progressive cavity pump to the bioprinting sector. I´m in this position for almost five years now.

Elisabeth Cobraiville

Elisabeth is a biomedical engineer specialized in biomaterials. She also holds a university certificate in Quality, Regulatory and Clinical Affairs of medical devices. Prior to joining CERHUM, she worked in a CRO and managed preclinical and clinical trials. She joined CERHUM almost 4 years ago and she is in charge of the products technical file, animal studies and clinical trials.

Daniel Kelly

Prof Daniel Kelly leads a multidisciplinary musculoskeletal tissue engineering group based in the Trinity Centre for Biomedical Engineering. The goal of his lab is to understand how environmental factors regulate the fate of adult progenitor cells and the tissues they produce. This research underpins a more translational programme aimed at developing novel tissue engineering and 3D bioprinting strategies to regenerate damaged and diseased musculoskeletal tissues. To date he has published over 200 articles in peer-reviewed journals. He is the recipient of four European Research Council awards (Starter grant 2010; Consolidator grant 2015; Proof of Concept grant 2017; Advanced grant 2021).

Denys Gurak

Denys Gurak is an experienced C-level manager and serial entrepreneur. He is a CEO and Co-Founder at A.D.A.M., a 3D bioprinting company with a primary focus on 3D-printed bones. Denys’s ultimate vision is to build an on-demand personalized tissue manufacturing platform that would be a one-stop shop for transplanted tissues and organs; and, hence, to cut barriers to medical treatment for millions. Denys’s passion for biotech can be traced back to 2010, when he was leading the international relations and certification, along with EU legislation adaptation at the Ukrainian medicinal products regulatory authority (official position – director of the «GMP/GDP Center» of the State Administration of Ukraine on Medicinal Products (SAUMP). In 2014 Denys joined the Ukrainian Defense Industry (a state defense conglomerate) in 2014 as the Deputy Director-General for foreign economic activity. During his time at the company, he managed the export-import operations that amounted to USD 1 billion yearly turnover. Furthermore, Denys represented Ukraine as the Head of Ukraine’s delegation to the NATO Industrial Advisory Group (NIAG), and led the industry transformation initiatives, including innovations development and technology JVs, as well international relations. Denys is a Venture Partner at ff Venture Capital a high-performing early stage venture firm based in NYC and Warsaw, Poland, focusing on disruptive IT, biotechnology, aerospace and security projects in CEE region.

Dan Rogozea

Dan Rogozea started working in the bioprinting field with the mission to produce the smallest bones in the human body, the ossicles. This project started in 2018 and initiated his work in the bioprinting field. In collaboration with Dr. Moldovan at the Roudebush VA Medical Center Bioprinting Core, he has continued to work in multiple projects in different fields ranging from cardiovascular to dental bioprinting projects. As an expert in the field Dan Rogozea continues to work in research and for well -known bioprinting companies.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

MELT

Melt-Electrowriting And/Or 3D Printing (Premium)

MELT electrowriting printing technology is a cutting-edge method that enables the precise fabrication of intricate structures at the micro- and nanoscale levels. This technology involves the controlled deposition of molten polymer fibers using electric fields, allowing for the creation of customized structures with high resolution and accuracy. In healthcare, MELT electrowriting has significant potential for various applications. For instance, it can be used to produce scaffolds for tissue engineering, where the precise arrangement of fibers can mimic the native tissue architecture and support cell growth and differentiation. Additionally, this technology can aid in developing drug delivery systems by creating microscale capsules or fibers capable of controlled release of therapeutic agents. Furthermore, MELT electrowriting has been explored to fabricate biosensors and diagnostic devices, offering a versatile and adaptable platform for advancing healthcare technologies.

Speakers:

Naomi Paxton

Dr. Naomi Paxton is a Senior Research Fellow in the field of biofabrication & 3D printing, and leader of the Bioinspired Additive Manufacturing (BioAM) group. With a background in physics, Naomi was part of the inaugural cohort for the dual international Biofabrication Masters degree and has completed her research training in world-leading international labs in Australia, Germany, the UK and USA. In 2020, Naomi completed her PhD in partnership with Melbourne-based medical device company, Anatomics, through the ARC Industrial Transformation Training Centre in Additive Biomanufacturing. Dr. Paxton’s research involves combining advanced biomaterials to 3D print scaffolds that replicate natural biological systems and promote regeneration. For example, Naomi’s research uses a range of biomaterials and composites to fabricate patient-specific surgical implants and focuses on the use of melt electrowriting (MEW), an advanced additive manufacturing technique which allows the deposition of micron-scale fibres in ordered 3D constructs.

Paul Dalton

Paul Dalton is an Associate Professor at the University of Oregon who specializes in manufacturing technologies for biofabrication. He is credited with inventing and developing melt electrowriting, a distinct class within 3D printing. His research on medical implants involves the use of high-resolution 3D printing and simultaneously promotes grassroots open-source hardware development and low-cost approaches in biomedical engineering. With over 25 years of hands-on experience, his expertise spans various fields, including biomaterials, nanotechnology, tissue engineering, neuroimmunology, experimental surgery, biofabrication, and 3D printing. His interdisciplinary and international perspective is reflected in his previous research and residences in Australia, Canada, China, the UK, and Germany before relocating to the US.

Bahram Mirani

Bahram Mirani is a Ph.D. candidate at the University of Toronto, working on tissue engineering of heart valves. Combining melt electrowriting with computational modelling and design of experiments, he has developed a method to recapitulate the complex nonlinear, anisotropic mechanical behaviour of native soft connective tissues such as valve tissue – essential for their function, regulation, and homeostasis – in tissue-engineered constructs. Before his Ph.D., Bahram obtained his Master’s degree in mechanical engineering from the University of Victoria, Canada, where he focused on tissue engineering, wound healing, and drug delivery.

Filippos Tourlomousis

Filippos is the founder & CEO of Biological Lattice Industries Corp., a VC-backed startup that is developing an AI-driven robotic biofabrication platform for tissue engineering and regenerative medicine applications. In addition to that, Filippos is the Chief Scientist of “Superlabs, The Laboratory for Autonomous Science” at NCSR Demokritos funded by the EU Resilience and Recovery Fund (Greece 2.0). His main research interests lie in the field of intelligence for the automation of science and robotics infrastructure for self-driving materials engineering labs of the future (a.k.a. “robot scientists”).

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Bioprinting Vasculatures (Premium)

3D bioprinting vasculatures is perhaps the holy grail of the next industrial revolution in healthcare. Biofabrication and bioprinting of any viable three-dimensional tissue will not be successful unless the vascularization challenge has been solved. Many organizations and talents around the world are actively tackling this challenge, but where are we exactly? Hear the latest perspectives, updates, and revelations from a group of technical and industrial superstars. 

Speakers:

Taci Pereira

Taci Pereira is Vice President and General Manager, Bioprinting at 3D Systems, where she leads the development and commercialization of research tools for 3D bioprinting applications. Taci was previously the Chief Scientific Officer at Allevi, a startup 3D Systems acquired in 2021. Taci leads the 3D bioprinting working group for the Regenerative Medicine Manufacturing Society, a professional society dedicated to advancing manufacturing solutions for the field of regenerative medicine. Originally from Curitiba, Brazil , She holds a Bachelor of Science in Bioengineering from Harvard University, where she worked at the Wyss Institute for Biologically Inspired Engineering. Taci’s research at the Mooney Laboratory for Cell and Tissue Engineering (Wyss) focused on biomaterials for cancer immunotherapy, under the advisory of David Mooney, Ph.D.

Ibrahim T. Ozbolat

Ibrahim Tarik Ozbolat is an Associate Professor of Engineering Science and Mechanics, Biomedical Engineering and Neurosurgery, and a member of the Huck Institutes of the Life Sciences at Penn State University. Dr. Ozbolat’s main area of research is in the field of 3D Bioprinting. He has been working on several aspects of bioprinting such as bioprinting processes, bioink materials, bioprinters and post-bioprinting tissue maturation for manufacturing of more than a dozen tissues and organs. Dr. Ozbolat is a leading scientist with over 150 publications, including a sole-authored book in his domain. Due to his notable contributions to the field of bioprinting, he has received several prestigious international and national awards including 2014 NSF CAREER Award, 2014 SME Outstanding Young Manufacturing Engineer Award, 2014 ASME Chao and Trigger Young Manufacturing Engineer Award, 2014 ASME Tau Pi Sigma Gold Medal, 2015 IIE Dr. Hamid K. Eldin Outstanding Early Career Industrial Engineer in Academia Award, 2015 International Outstanding Young Researcher in Freeform and Additive Manufacturing Award and 2017 Hartz Family Career Development Professorship at Penn State.

Marc Thurner

Marc Thurner is a visionary, entrepreneur and pioneer in biofabrication technologies, currently acting as Chief Executive Officer at mimiX biotherapeutics Ltd. He pioneered the field of 3D bioprinting with his former creation regenHU Ltd, today recognized as an industry leader in the development of innovative biomedical solutions. A micro technology engineer Graduate, Marc started his professional career as an R&D engineer, managing international projects for the high precision automation industry. His avant-gardiste view that the future of regenerative medicine lay in converging engineering and biomedical science, brought him to found regenHU Ltd in 2007 and mimiX biotherapeutics Ltd in 2020. In 2012 Marc created the regenHU spin-off Vivos Dental Ltd, specialized in innovative 3D-printed bone grafting solutions for oral bone augmentation. Being an industry transformation leader, mimiX biotherapeutics develops leading-edge solutions in biotechnology and tissue engineering that enable scientific and clinical breakthroughs. The Swiss-based company collaborates with a global network of scientific innovators and industry players and leads the development of biomedical products for regenerative medicine and drug discovery. Marc Thurner and the mimiX biotherapeutics team are passionate about addressing the current and next generation biotechnology challenges to help the progress of Life Sciences.

Pierre-Alexandre LAURENT, PhD

During my PhD, I worked on the role of PI3Ks on the platelet functions and thrombus formation using in particular microfluidic/videomicroscopy technics. My postdoc research was focused on the development of 3D bone marrow models for the study of thrombocytopenia, developping bioreactor for ex-vivo platelet production and drug testing purposes using silk fibroin biomaterial and 3D bioprinting approach. I am now Senior Field Application Scientist at CELLINK, a BICO company promoting how our amazing bioconvergence technologies contribute to the future of biomedical research.

Moderator:

William Harley

William is a Ph.D. candidate within the School of Biomedical Engineering at the University of Melbourne. He obtained a certificate 3 in business management and an honors degree in medical biotechnology from the University of New South Wales where he first entered research focusing on biomaterials, stem cells, and nanofabrication processes for tissue regeneration. Currently, his Ph.D. investigates the use of acoustic micromanipulation and 3D bioprinting as tools to pattern and define the cellular microenvironment. William has held roles as a research assistant and a business development consultant, where he currently serves as a community and events manager for 3D Heals and an organizing committee member for the Australian Bioprinting Workshop.

3D Microfabrication: Medical Applications (Premium)

What is microfabrication? Based on the latest definition, microfabrication is “a collection of technologies which are utilized in making microdevices.” As the name implies, 3D microfabrication is the manufacturing technique using layering of materials to produce a 3D structure at a typical scale of micrometer or even nanometer dimension. In other words, 3D printing at micro or nanometer scale. One commonly known 3D microfabrication or additive manufacturing microdevice process that can achieve this level of resolution includes 3D laser microfabrication such as laser direct-writing (LDW). Microfluidic devices are often produced using LDW. Microstereolithography, another common technique based on stereolithography principles fabricates 3D components by repeatedly layering photopolymerizable resin and curing under an ultraviolet laser. Finally, multiphoton lithography (e.g. two photopolymerizations) is another recognized 3D microfabrication process that can 3D printing sub-micrometer resolution). Over the past several years, there is an increasing interest in the space with a handful of new startups more visible in the spotlight in the 3D printing space. One of the driving forces is the enormous need to mass manufacture complex but small (if not smaller) medical devices. Examples include stents, microneedles, endoscopic components, and many others that are facing size challenges. Another driving force is the potential point of care of these devices meeting the design and manufacturing demand without facing external competition, trade secret loss, and supply chain crisis.

Speakers:

John Kawola

CEO of Boston Micro Fabrication

John is the CEO of Boston Micro Fabrication (BMF) an additive manufacturing technology company with a focus on high resolution, accuracy, and precision. From 2016 to 2019, John served as President-Americas for Ultimaker, the leading open-source desktop 3D printing company. From 2012 to 2016, John was the CEO of Harvest Automation. Harvest developed and deployed an autonomous mobile robotic platform that assists workers with difficult, repetitive material handling. John was VP of Sales and then CEO of Z Corporation from 1997 until 2012. Z Corporation led the way in introducing fast, easy to use and full-color 3D printing into a wide range of industries. John is also currently the Chairman of Labminds, a laboratory automation technology company, and a Board Director at Industrial ML, an industrial machine learning company. John received a BS in Mechanical Engineering from Cornell University, MS in Mechanical Engineering from Rensselaer, and an MBA from Union College.

Adam Steege

Adam Steege

After completing undergraduate work in Math, Physics, and Mechanical Engineering, Adam started his first company, Agile EndoSurgery. Agile developed novel articulated laparoscopic surgical devices, using a wide variety of fabrication techniques. Through this development process, as well as through his consulting work that resulted in the development of 3 other commercialized medical devices, Adam learned the potential and the shortcomings of 3d printing in medtech. With over 80 pending and issued patents, and 10 years of medical device development in addition to automation, robotics, and manufacturing expertise, Adam founded Trio Labs to solve the problems of precision and scalability in metal additive manufacturing.

Martin Hermatschweiler

Martin is CEO of Nanoscribe, the pioneer and market leader in high-precision additive manufacturing. Various, application-specific products underpin the expertise for specialized manufacturing scenarios such as prototyping, mastering, alignment with nanoprecision, and bioprinting. Nanoscribe is a spin-off of the Karlsruhe Institute of Technology (KIT) and belongs to the BICO Group since June 2021. With Nanoscribe, the BICO Group is the world’s first life science company with internal Two-Photon Polymerization (2PP) additive manufacturing capabilities. Martin is co-founder and managing partner of Nanoscribe, ever since the company was founded in 2007. The scientific expertise of the graduate physicist lies in laser patterning of polymers as well as in their casting into high refractive index optical materials. In 2015, he has been listed among the TOP 40 entrepreneurs within Germany younger than 40 years by the journal “Capital”, the so-called “young elite”.

Albert Folch

Albert Folch’s lab works at the interface between 3D-printing, microfluidics and cancer. He received both his BSc (1989) and PhD (1994) in Physics from the University of Barcelona (UB), Spain, in 1989. During his Ph.D. he was a visiting scientist from 1990–91 at the Lawrence Berkeley Lab working on AFM under Dr. Miquel Salmeron. From 1994–1996, he was a postdoc at MIT developing MEMS under Martin Schmidt (EECS) and Mark Wrighton (Chemistry). In 1997, he joined Mehmet Toner’s lab as a postdoc at Harvard-MGH to apply soft lithography to tissue engineering. He has been at Seattle’s UW BioE since June 2000, where he is now a full Professor, accumulating over 11,000 citations. In 20 years, he has supervised 18 postdocs (17% of whom have reached faculty rank), 12 Ph.D. students (25% faculty rank), 15 M.S. students, and >40 undergraduates. In 2001 he received an NSF Career Award, in 2006 a NASA Space Act Award, and in 2014 he was elected to the AIMBE College of Fellows (Class of 2015). He has served on the Advisory Board of Lab on a Chip between 2006-2017 and on the Editorial Board of Micromachines since 2019. He is the sole author of 5 books, including “Introduction to BioMEMS” (2012, Taylor&Francis), a textbook adopted by ~100 departments in 18 countries, and “Hidden in Plain Sight: The History, Science, and Engineering of Microfluidic Technology” (MIT Press, to appear in April 2022). Since 2007, the lab runs a celebrated outreach art program called BAIT (Bringing Art Into Technology), which has produced seven exhibits, a popular resource gallery of >2,000 free images related to microfluidics and microfabrication, and a YouTube channel that plays microfluidic videos with music which accumulates ~157,000 visits since 2009.

Abstract: 

The miniaturization of biomedical assays is of paramount importance for expanding healthcare access, for reducing healthcare costs, and for expediting biological research. However, biologists and clinicians typically do not have access to microfluidic technology because they do not have the engineering expertise or equipment required to fabricate and/or operate microfluidic devices. Furthermore, the present commercialization path for microfluidic devices is usually restricted to high-volume applications in order to recover the large investment needed to develop the plastic molding processes. We are developing microfluidic devices through stereolithography, a high-resolution form of 3D printing, in order to make microfluidic technology readily available via the web to biomedical scientists. Most available SL resins do not have all the favorable physicochemical properties of the above-named plastics (e.g., biocompatibility, transparency, elasticity, and gas permeability), so the performance of SL-printed devices is still inferior to that of equivalent PDMS devices. Inspired by the success of hydrogel PEG-DA biocompatibility, we have developed microfluidic devices by SL in resins that share all the advantageous attributes of PDMS and thermoplastics so that we can 3D-print designs with comparable performance and biocompatibility to those that are presently molded.

Moderator:

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.